BioPharmSignal logoBioPharmSignal

Biotech News

Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Enliven Therapeutics (ELVN)Enliven TherapeuticsEarnings

Reported positive initial Phase 1b data for ELVN-001 in CML Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026 Key data readout, regulatory interactions, and operational catalysts throughout 2026 Strong balance sheet with $463 million in cash, cash

Open original release

Related news

ELVNEnliven Therapeutics2026-05-07 20:05 EST

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

ELVNEnliven Therapeutics2026-06-03 20:05 EST

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

FATEFate Therapeutics2026-05-13 12:30 EST

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

ARGXArgenx2026-07-23 05:00 EST

argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

ARGXArgenx2026-07-16 05:00 EST

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

FATEFate Therapeutics2026-07-01 20:05 EST

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

MGNXMacroGenics2026-05-13 20:01 EST

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

ZNTLZentalis2026-05-12 20:05 EST

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

IMTXImmatics2026-05-12 11:00 EST

Immatics Announces First Quarter 2026 Financial Results and Business Update

View all latest news

Enliven Therapeutics

Enliven Therapeutics is an oncology company focused on targeted therapies and precision cancer medicine. Its development strategy emphasizes genetically defined cancers and differentiated molecules.

Recent company news

ELVNEnliven Therapeutics2026-06-03 20:05 EST

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

ELVNEnliven Therapeutics2026-05-21 20:05 EST

Enliven Therapeutics to Present at Upcoming Investor Conferences

ELVNEnliven Therapeutics2026-05-12 13:53 EST

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

ELVNEnliven Therapeutics2026-05-07 20:05 EST

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

ELVNEnliven Therapeutics2026-03-03 21:05 EST

Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Stock data

Close
52.74 USD
Market cap
2.16B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States